Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely employed in the treatment of musculoskeletal disorders but their use is limited by adverse effects on the gastrointestinal tract. A new class of NSAIDs, containing a nitric oxide (NO)-donor moiety (NO-NSAID) has been developed which retain the desired anti-inflammatory and analgaesic properties of NSAIDs but which do not cause gastrointestinal side effects, because the vasodilator effects of NO counteract the adverse effects of COX-1 inhibition on gastric mucosa [1,2]. Previous studies have shown that prostaglandins and nitric oxide play an important role in regulating bone cell function [3,4]. Since NO-NSAIDs combine the properties of a NO donor with those of a COX inhibitor, we have investigated the effects of the NO-NSAID flurbiprofen nitroxybutylester (HCT1026) on bone resorption in vitro and in vivo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
